Cancer Res Treat.  2009 Mar;41(1):1-11.

Advances of Cancer Therapy by Nanotechnology

• Wang X
• Wang Y
• Chen ZG
• Shin DM

Abstract

Recent developments in nanotechnology offer researchers opportunities to significantly transform cancer therapeutics. This technology has enabled the manipulation of the biological and physicochemical properties of nanomaterials to facilitate more efficient drug targeting and delivery. Clinical investigations suggest that therapeutic nanoparticles can enhance efficacy and reduced side effects compared with conventional cancer therapeutic drugs. Encouraged by rapid and promising progress in cancer nanotechnology, researchers continue to develop novel and efficacious nanoparticles for drug delivery. The use of therapeutic nanoparticles as unique drug delivery systems will be a significant addition to current cancer therapeutics.

Keyword

Nanoparticels; Cancer therapy; Drug delivery

MeSH Terms

Drug Delivery Systems
Nanoparticles
Nanostructures
Nanotechnology

Figure

• 

  Fig. 1 Illustration of (A) polymer based nanoparticles; (B). Liposome based nanoparticles; and (C). Iron oxide or gold nanoparticles.

• 

  Fig. 2 Schematic diagram of nanoparticle accumulation in tumor tissue through EPR effect. Normal tissue vasculatures are lined by tight endothelial cells, thereby preventing nanoparticle drugs from escaping, whereas tumor tissue vasculatures are leaky and hyperpermeable allowing preferential accumulation of nanoparticles in the tumor interstitial space (passive targeting).

• 

  Fig. 3 Internalization of nanoparticles via receptor-mediated endocytosis. Tumor-specific ligands/antibodies on the nanoparticles bind to cell through an endosome-dependent mechanism. Drug-loaded nanoparticles bypass the drug efflux pump not being recognized when the drug enters cells, leading to high intracellular concentration.

Reference

1. Qiu LY, Bae YH. Polymer architecture and drug delivery. Pharm Res. 2006; 23:1–30. PMID: 16392022.

2. Tong R, Cheng JJ. Anticancer polymeric nanomedicines. Polym Rev. 2007; 47:345–381.

3. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008; 14:1310–1316. PMID: 18316549.

4. Zhang GZ, Niu AZ, Peng SF, Jiang M, Tu YF, Li M, et al. Formation of novel polymeric nanoparticles. Acc Chem Res. 2001; 34:249–256. PMID: 11263883.

5. Park K, Kim K, Kwon IC, Kim SK, Lee S, Lee DY, et al. Preparation and characterization of self-assembled nanoparticles of heparin-deoxycholic acid conjugates. Langmuir. 2004; 20:11726–11731. PMID: 15595804.

6. Park K, Lee GY, Kim YS, Yu M, Park RW, Kim IS, et al. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J Control Release. 2006; 114:300–306. PMID: 16884806.

7. Kratz F, Beyer U, Schutte MT. Drug-polymer conjugates containing acid-cleavable bonds. Crit Rev Ther Drug Carrier Syst. 1999; 16:245–288. PMID: 10706520.

8. Ulbrich K, Subr V. Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev. 2004; 56:1023–1050. PMID: 15066758.

9. Jones DP, Carlson JL, Samiec PS, Sternberg P, Mody VC, Reed RL, et al. Glutathione measurement in human plasma Evaluation of sample collection, storage and derivatization conditions for analysis of dansyl derivatives by HPLC. Clin Chim Acta. 1998; 275:175–184. PMID: 9721075.

10. Koo AN, Lee HJ, Kim SE, Chang JH, Park C, Kim C, et al. Disulfide-cross-linked PEG-poly(amino acid)s copolymer micelles for glutathione-mediated intracellular drug delivery. Chem Commun (Camb). 2008; 6570–6572. PMID: 19057782.

11. Bosman AW, Janssen HM, Meijer EW. About dendrimers: Structure, physical properties, and applications. Chem Rev. 1999; 99:1665–1688. PMID: 11849007.

12. Fischer M, Vogtle F. Dendrimers: From design to application - A progress report. Angew Chem Int Ed Engl. 1999; 38:885–905.

13. Klajnert B, Bryszewska M. Dendrimers: properties and applications. Acta Biochimica Polonica. 2001; 48:199–208. PMID: 11440170.

14. Dykes GM. Dendrimers: a review of their appeal and applications. J Chem Tech Biot. 2001; 76:903–918.

15. Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today. 2001; 6:427–436. PMID: 11301287.

16. Balogh L, Tomalia DA. Poly(amidoamine) dendrimer-templated nanocomposites. 1. Synthesis of zerovalent copper nanoclusters. J Am Chem Soc. 1998; 120:7355–7356.

17. Crooks RM, Zhao MQ, Sun L, Chechik V, Yeung LK. Dendrimer-encapsulated metal nanoparticles: Synthesis, characterization, and applications to catalysis. Acc Chem Res. 2001; 34:181–190. PMID: 11263876.

18. Balogh L, Bielinska A, Eichman JD, Valluzzi R, Lee I, Baker JR, et al. Dendrimer nanocomposites in medicine. Chim Oggi. 2002; 20:35–40.

19. Zheng J, Dickson RM. Individual water-soluble dendrimer-encapsulated silver nanodot fluorescence. J Am Chem Soc. 2002; 124:13982–13983. PMID: 12440882.

20. Bangham AD, Horne RW. Negative Staining of Phospholipids + Their Structural Modification by-Surface Active Agents as Observed in Electron Microscope. J Mol Biol. 1964; 8:660–668. PMID: 14187392.

21. Watwe RM, Bellare JR. Manufacture of Liposomes - a Review. Curr Sci. 1995; 68:715–724.

22. Gabizon AA. Stealth liposomes and tumor targeting: One step further in the quest for the magic bullet. Clin Cancer Res. 2001; 7:223–225. PMID: 11234871.

23. Cheng Y, Samia AC, Meyers JD, Panagopoulos I, Fei BW, Burda C. Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J Am Chem Soc. 2008; 130:10643–10647. PMID: 18642918.

24. Qian X, Peng XH, Ansari DO, Yin-Goen Q, Chen GZ, Shin DM, et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol. 2008; 26:83–90. PMID: 18157119.

25. Dewey WC. Arrhenius Relationships from the Molecule and Cell to the Clinic. Int J Hyperthermia. 1994; 10:457–483. PMID: 7963805.

26. Sun C, Lee JSH, Zhang MQ. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008; 60:1252–1265. PMID: 18558452.

27. Jun YW, Lee JH, Cheon J. Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. Angew Chem Int Ed Engl. 2008; 47:5122–5135. PMID: 18574805.

28. Xu CJ, Sun SH. Monodisperse magnetic nanoparticles for biomedical applications. Polym Int. 2007; 56:821–826.

29. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7:771–782. PMID: 18758474.

30. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004; 22:969–976. PMID: 15258594.

31. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm. 2005; 2:194–205. PMID: 15934780.

32. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006; 25:4633–4646. PMID: 16892078.

33. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006; 25:9–34. PMID: 16680569.

34. Edens HA, Levi BP, Jaye DL, Walsh S, Reaves TA, Turner JR, et al. Neutrophil transepithelial migration: evidence for sequential, contact-dependent signaling events and enhanced paracellular permeability independent of transjunctional migration. J Immunol. 2002; 169:476–486. PMID: 12077279.

35. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin. 2008; 58:97–110. PMID: 18227410.

36. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987; 6:559–593. PMID: 3327633.

37. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004; 56:1649–1659. PMID: 15350294.

38. Cuenca AG, Jiang H, Hochwald SN, Delano M, Cance WG, Grobmyer SR. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer. 2006; 107:459–466. PMID: 16795065.

39. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004; 303:1818–1822. PMID: 15031496.

40. Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res. 2007; 24:1029–1046. PMID: 17385025.

41. Weissig V, Whiteman KR, Torchilin VP. Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice. Pharm Res. 1998; 15:1552–1556. PMID: 9794497.

42. Papahadjopoulos D, Gabizon A. Liposomes designed to avoid the reticuloendothelial system. Prog Clin Biol Res. 1990; 343:85–93. PMID: 2198586.

43. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol. 2006; 24:1211–1217. PMID: 17033654.

44. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res. 2005; 11:4136–4143. PMID: 15930349.

45. Boddy AV, Plummer ER, Todd R, Sludden J, Griffin M, Robson L, et al. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res. 2005; 11:7834–7840. PMID: 16278406.

46. Schluep T, Cheng J, Khin KT, Davis ME. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol. 2006; 57:654–662. PMID: 16133526.

47. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23:7794–7803. PMID: 16172456.

48. Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer. 2005; 92:1240–1246. PMID: 15785749.

49. Kato K, Hamaguchi T, Yasui H, Okusaka T, Ueno H, Ikeda M, et al. Phase I study of NK105, a paclitaxel-incorporating micellar nanoparticle in patients with advanced cancer. Proc Am Soc Clin Oncol. 2006; 24:83S. (abstract 2018).

50. Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, Ueno H, et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer. 2007; 97:170–176. PMID: 17595665.

51. Charrois GJ, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta. 2004; 1663:167–177. PMID: 15157619.

52. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer. 2004; 91:1775–1781. PMID: 15477860.

53. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res. 2000; 60:4251–4255. PMID: 10945638.

54. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006; 66:6732–6740. PMID: 16818648.

55. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A. 2007; 104:15549–15554. PMID: 17875985.

56. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006; 103:6315–6320. PMID: 16606824.

57. Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A. 2008; 105:2586–2591. PMID: 18272481.

58. Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol. 2004; 15:517–525. PMID: 14998859.

59. MedBiopharm Co. L.Safety study of MBP-426 (liposomal oxaliplatin suspension for injection) to treat advanced or metastatic solid tumors. ClinivalTrials.gov web site 2008 [online]. http;//www.clinicaltrials.gov/ct/show/NCT00355888/.

60. SynerGene Therapeutics I. safety study of infusion of SGT-53 tp treat solid tumors. ClinicalTrials.gov web site 2008 [online]. http://www.clincaltrials.gov/ct2/show/NCT00470613/.

61. Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A. 2007; 104:5715–5721. PMID: 17379663.

62. Calando-Pharmaceuticals. Safety study of CALAA-01 to treat solid tumor cancers. ClinicalTrials.gov web site 2008 [online]. http://www.clincaltrials.gov/ct/show/NCT00689065.

63. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol. 1983; 36:539–545. PMID: 6302135.

64. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008; 105:17356–17361. PMID: 18978032.

65. Mansour AM, Drevs J, Esser N, Hamada FM, Badary OA, Unger C, et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 2003; 63:4062–4066. PMID: 12874007.

66. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000; 60:6950–6957. PMID: 11156395.

67. Guillemard V, Uri Saragovi H. Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene. 2004; 23:3613–3621. PMID: 15034547.

68. Guillemard V, Saragovi HU. Novel approaches for targeted cancer therapy. Curr Cancer Drug Targets. 2004; 4:313–326. PMID: 15180497.

69. Pechar M, Ulbrich K, Subr V, Seymour LW, Schacht EH. Poly(ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin. Bioconjug Chem. 2000; 11:131–139. PMID: 10725088.

70. Lu ZR, Gao SQ, Kopeckova P, Kopecek J. Modification of cyclosporin A and conjugation of its derivative to HPMA copolymers. Bioconjug Chem. 2001; 12:129–133. PMID: 11170375.

71. Li C. Poly(L-glutamic acid)--anticancer drug conjugates. Adv Drug Deliv Rev. 2002; 54:695–713. PMID: 12204599.

72. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000; 41:147–162. PMID: 10699311.

73. Ni S, Stephenson SM, Lee RJ. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells. Anticancer Res. 2002; 22:2131–2135. PMID: 12174894.

74. Backer MV, Gaynutdinov TI, Aloise R, Przekop K, Backer JM. Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery. Protein Expr Purif. 2002; 26:455–461. PMID: 12460770.

75. Backer MV, Aloise R, Przekop K, Stoletov K, Backer JM. Molecular vehicles for targeted drug delivery. Bioconjug Chem. 2002; 13:462–467. PMID: 12009934.

76. Saba NF, Wang X, Müller S, Tighiouart M, Cho K, Nie S, Chen Z(G), Shin DM. Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug. Head and Neck. 2008; in press.

77. Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer. 1996; 32A:1070–1081. PMID: 8763349.

78. McDevitt CA, Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther. 2007; 113:429–441. PMID: 17208306.

79. Pepin X, Attali L, Domrault C, Gallet S, Metreau JM, Reault Y, et al. On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level. J Chromatogr B Biomed Sci Appl. 1997; 702:181–191. PMID: 9449570.

80. Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release. 2003; 93:151–160. PMID: 14636721.

81. Peracchia MT, Fattal E, Desmaele D, Besnard M, Noel JP, Gomis JM, et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release. 1999; 60:121–128. PMID: 10370176.

82. Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res. 2006; 12:1606–1614. PMID: 16533788.

83. Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol. 1997; 15:653–659. PMID: 9053490.

84. Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat. 2003; 6:271–279. PMID: 14643297.

85. Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008; 108:241–250. PMID: 17476588.

86. Nemunaitis J, Cunningham C, Senzer N, Gray M, Oldham F, Pippen J, et al. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. Cancer Invest. 2005; 23:671–676. PMID: 16377585.

87. Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release. 2005; 103:405–418. PMID: 15763623.

88. Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm. 2005; 2:373–383. PMID: 16196490.

89. Rihova B, Riha I. Immunological problems of polymer-bound drugs. Crit Rev Ther Drug Carrier Syst. 1985; 1:311–374. PMID: 2420476.

90. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003; 2:347–360. PMID: 12750738.

91. Cagle DW, Kennel SJ, Mirzadeh S, Alford JM, Wilson LJ. In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers. Proc Natl Acad Sci U S A. 1999; 96:5182–5187. PMID: 10220440.

92. Ogawara K, Furumoto K, Takakura Y, Hashida M, Higaki K, Kimura T. Surface hydrophobicity of particles is not necessarily the most important determinant in their in vivo disposition after intravenous administration in rats. J Control Release. 2001; 77:191–198. PMID: 11733087.

93. Fernandez-Urrusuno R, Fattal E, Porquet D, Feger J, Couvreur P. Evaluation of liver toxicological effects induced by polyalkylcyanoacrylate nanoparticles. Toxicol Appl Pharmacol. 1995; 130:272–279. PMID: 7871540.

94. Roberts JC, Bhalgat MK, Zera RT. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J Biomed Mater Res. 1996; 30:53–65. PMID: 8788106.

95. Neerman MF, Zhang W, Parrish AR, Simanek EE. In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery. Int J Pharm. 2004; 281:129–132. PMID: 15288350.

96. Wang B, Feng WY, Wang TC, Jia G, Wang M, Shi JW, et al. Acute toxicity of nano- and micro-scale zinc powder in healthy adult mice. Toxicol Lett. 2006; 161:115–123. PMID: 16165331.

97. Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH, Schot M, Mandjes IA, Zurlo MG, et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs. 2001; 12:315–323. PMID: 11335787.

98. Wachters FM, Groen HJ, Maring JG, Gietema JA, Porro M, Dumez H, et al. A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. Br J Cancer. 2004; 90:2261–2267. PMID: 15150611.

99. Clift MJ, Rothen-Rutishauser B, Brown DM, Duffin R, Donaldson K, Proudfoot L, et al. The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line. Toxicol Appl Pharmacol. 2008; 232:418–427. PMID: 18708083.

100. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 2005; 65:5317–5324. PMID: 15958579.

101. Benny O, Fainaru O, Adini A, Cassiola F, Bazinet L, Adini I, et al. An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat Biotechnol. 2008; 26:799–807. PMID: 18587385.

102. Langer CJ. CT-2103: emerging utility and therapy for solid tumours. Expert Opin Investig Drugs. 2004; 13:1501–1508.

103. Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomedicine. 2007; 2:567–583. PMID: 18203425.

104. Batist G. Cardiac safety of liposomal anthracyclines. Cardiovasc Toxicol. 2007; 7:72–74. PMID: 17652807.

105. Fassas A, Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma. 2005; 46:795–802. PMID: 16019523.

106. Allison SD. Liposomal drug delivery. J Infus Nurs. 2007; 30:89–95. PMID: 17413493.

107. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv. 2005; 2:369–381. PMID: 16305440.

108. White SC, Lorigan P, Margison GP, Margison JM, Martin F, Thatcher N, et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer. 2006; 95:822–828. PMID: 16969346.

109. Rosenthal DI, Yom SS, Liu L, Machtay M, Algazy K, Weber RS, et al. A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest New Drugs. 2002; 20:343–349. PMID: 12201498.

110. Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol. 2001; 12:493–496. PMID: 11398881.

111. Neville ME, Boni LT, Pflug LE, Popescu MC, Robb RJ. Biopharmaceutics of liposomal interleukin 2, oncolipin. Cytokine. 2000; 12:1691–1701. PMID: 11052821.

112. Ciuleanu T, Diculescu M, Hoepffner NM, Trojan J, Sailer V, Zalupski M, et al. A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers. Invest New Drugs. 2007; 25:385–390. PMID: 17364234.

113. Clamp AR, Schoffski P, Valle JW, Wilson RH, Marreaud S, Govaerts AS, et al. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2008; 61:579–585. PMID: 17520255.

114. Guo W, Johnson JL, Khan S, Ahmad A, Ahmad I. Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study. Anal Biochem. 2005; 336:213–220. PMID: 15620886.

115. Seiden MV, Muggia F, Astrow A, Matulonis U, Campos S, Roche M, et al. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol. 2004; 93:229–232. PMID: 15047241.

116. Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol. 2006; 58:759–764. PMID: 16847673.

117. Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007; 18:2009–2014. PMID: 17785767.

118. Kim SI, Shin D, Choi TH, Lee JC, Cheon GJ, Kim KY, et al. Systemic and Specific Delivery of Small Interfering RNAs to the Liver Mediated by Apolipoprotein A-I. Mol Ther. 2007; 1145–1152. PMID: 17440441.

119. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004; 10:3708–3716. PMID: 15173077.

120. Matsumura Y. [Micelle carrier system in clinical trial]. Nippon Rinsho. 2006; 64:316–321. PMID: 16454187.

121. Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer. 2004; 90:2085–2091. PMID: 15150584.

122. Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer. 2005; 93:678–687. PMID: 16222314.

123. Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T, et al. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 2006; 66:10048–10056. PMID: 17047068.

124. Negishi T, Koizumi F, Uchino H, Kuroda J, Kawaguchi T, Naito S, et al. NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. Br J Cancer. 2006; 95:601–606. PMID: 16909136.

125. Albain KS, Belani CP, Bonomi P, O'Byrne KJ, Schiller JH, Socinski M. PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer. 2006; 7:417–419. PMID: 16800969.

126. Bilim V. Technology evaluation: PK1, Pfizer/Cancer Research UK. Curr Opin Mol Ther. 2003; 5:326–330. PMID: 12870445.

127. Thomson AH, Vasey PA, Murray LS, Cassidy J, Fraier D, Frigerio E, et al. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. Br J Cancer. 1999; 81:99–107. PMID: 10487619.

128. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002; 20:1668–1676. PMID: 11896118.

129. Bissett D, Cassidy J, de Bono JS, Muirhead F, Main M, Robson L, et al. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br J Cancer. 2004; 91:50–55. PMID: 15187995.

130. Sarapa N, Britto MR, Speed W, Jannuzzo M, Breda M, James CA, et al. Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma. Cancer Chemother Pharmacol. 2003; 52:424–430. PMID: 12904897.

131. Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, et al. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res. 2004; 10:3386–3395. PMID: 15161693.

132. Campone M, Rademaker-Lakhai JM, Bennouna J, Howell SB, Nowotnik DP, Beijnen JH, et al. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother Pharmacol. 2007; 60:523–533. PMID: 17308894.

133. Danhauser-Riedl S, Hausmann E, Schick HD, Bender R, Dietzfelbinger H, Rastetter J, et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs. 1993; 11:187–195. PMID: 7505268.

134. Shiose Y, Kuga H, Yamashita F, Hashida M. Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f. J Pharm Biomed Anal. 2007; 43:1290–1296. PMID: 17127025.

135. Soepenberg O, de Jonge MJ, Sparreboom A, de Bruin P, Eskens FA, de Heus G, et al. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin Cancer Res. 2005; 11:703–711. PMID: 15701859.

136. Ochi Y, Shiose Y, Kuga H, Kumazawa E. A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951. Cancer Chemother Pharmacol. 2005; 55:323–332. PMID: 15517271.

137. Greenwald RB, Choe YH, McGuire J, Conover CD. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev. 2003; 55:217–250. PMID: 12564978.

138. Rowinsky EK, Rizzo J, Ochoa L, Takimoto CH, Forouzesh B, Schwartz G, et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol. 2003; 21:148–157. PMID: 12506184.

139. Sapra P, Zhao H, Mehlig M, Malaby J, Kraft P, Longley C, et al. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res. 2008; 14:1888–1896. PMID: 18347192.

140. NektarTherapeutics. Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Breast Cancer. Clinical Trials.gov web site 2008 [online]. http://clinicaltrials.gov/ct2/show/NCT00802945.

141. Gradishar WJ. Albumin-bound nanoparticle paclitaxel. Clin Adv Hematol Oncol. 2005; 3:348–349. PMID: 16167008.

142. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006; 7:1041–1053. PMID: 16722814.

143. Yoo HS, Park TG. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release. 2004; 100:247–256. PMID: 15544872.

144. Nasongkla N, Shuai X, Ai H, Weinberg BD, Pink J, Boothman DA, et al. cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew Chem Int Ed Engl. 2004; 43:6323–6327. PMID: 15558662.

145. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A. 2003; 100:6039–6044. PMID: 12716967.

146. Jeong YI, Seo SJ, Park IK, Lee HC, Kang IC, Akaike T, et al. Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(gamma-benzyl L-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int J Pharm. 2005; 296:151–161. PMID: 15885467.